Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription Articles published in Oncol Rep Retrieve available abstracts of 26 articles: HTML format

Single Articles

March 2025
1. LIU YH, Zhu M, Lei PP, Pan XY, et al
   [Corrigendum] ND?09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR?ABL signaling.
   Oncol Rep. 2025;53:37.
   PubMed     Abstract available
   
   
   November 2024
2. CHEN L, Zeng P, Tang H, Chen G, et al
   Routes and molecular mechanisms of central nervous system involvement in acute myeloid leukemia (Review).
   Oncol Rep. 2024;52:146.
   PubMed     Abstract available
   
   
   August 2024
3. MORINO Y, Sugiyama H, Yamane K, Kikuchi M, et al
   Additive antitumor effect of arsenic trioxide with exposure to ionizing radiation to human acute promyelocytic leukemia HL?60 cells.
   Oncol Rep. 2024;52:109.
   PubMed     Abstract available
   
   
   July 2024
4. IDA N, Okura M, Tanaka S, Hosono N, et al
   Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair.
   Oncol Rep. 2024;52:90.
   PubMed     Abstract available
   
   
   May 2024
5. TENG Z, Xu S, Lei Q
   [Retracted] Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB?152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
   Oncol Rep. 2024;51:66.
   PubMed     Abstract available
   
   
   December 2023
6. LI J, Tang B, Miao Y, Li G, et al
   Targeting of STAT5 using the small molecule topotecan hydrochloride suppresses acute myeloid leukemia progression.
   Oncol Rep. 2023;50:208.
   PubMed     Abstract available
   
   
   August 2023
7. WANG X, Rong S, Sun Y, Yin B, et al
   NDRG3 regulates imatinib resistance by promoting beta‑catenin accumulation in the nucleus in chronic myelogenous leukemia.
   Oncol Rep. 2023;50:152.
   PubMed     Abstract available
   
   
   May 2023
8. LIU YH, Zhu M, Lei PP, Pan XY, et al
   [Corrigendum] ND‑09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR‑ABL signaling.
   Oncol Rep. 2023;49:81.
   PubMed     Abstract available
   
   
   February 2023
9. LIANG X, Xia R
   [Corrigendum] Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia.
   Oncol Rep. 2023;49:26.
   PubMed     Abstract available
   
   
   December 2022
10. LEONCINI PP, Vitullo P, Reddel S, Tocco V, et al
    MicroRNA profiling of paediatric AML with FLT-ITD or MLL-rearrangements: Expression signatures and in vitro modulation of miR-221-3p and miR-222-3p with BRD4/HATs inhibitors.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    August 2022
11. KAEHLER M, Litterst M, Kolarova J, Bohm R, et al
    Genomewide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitorresistant CML cells.
    Oncol Rep. 2022;48.
    PubMed     Abstract available
    
    
    June 2022
12. LALIC H, Aurer I, Batinic D, Visnjic D, et al
    Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    May 2022
13. FORGIONE MO, McClure BJ, Page EC, Yeung DT, et al
    TP53 lossoffunction mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    April 2022
14. LI Z, Zhang J, Zhou M, Li JL, et al
    Epigenetic therapy with chidamide alone or combined with 5azacitidine exerts antitumour effects on acute myeloid leukaemia cells in vitro.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    February 2022
15. HUANG FL, Yu SJ, Liao EC, Li LY, et al
    Niclosamide suppresses Tcell acute lymphoblastic leukemia growth through activation of apoptosis and autophagy.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    January 2022
16. LIANG X, Xia R
    Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia.
    Oncol Rep. 2022;47.
    PubMed     Abstract available
    
    
    October 2021
17. AYE KT, Wattanapongpitak S, Supawat B, Kothan S, et al
    Gallic acid enhances pirarubicininduced anticancer in living K562 and K562/Dox leukemia cancer cells through cellular energetic state impairment and Pglycoprotein inhibition.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    July 2021
18. YAO J, Luo Y, Zeng C, He H, et al
    UHRF1 regulates the transcriptional repressor HBP1 through MIF in T acute lymphoblastic leukemia.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
19. SHI YF, Huang ZY, Huang YS, Dong RJ, et al
    Interaction between CD9 and PI3Kp85 activates the PI3K/AKT signaling pathway in Blineage acute lymphoblastic leukemia.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
20. LIU YH, Zhu M, Lei PP, Pan XY, et al
    ND09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCRABL signaling.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    
21. FU JF, Shih LY, Yen TH
    HOXA11 plays critical roles in disease progression and response to cytarabine in AML.
    Oncol Rep. 2021;46.
    PubMed     Abstract available
    
    
    June 2021
22. DONG L, Xu WW, Li H, Bi KH, et al
    [Retracted] In vitro and in vivo anticancer effects of marmesin in U937 human leukemia cells are mediated via mitochondrialmediated apoptosis, cell cycle arrest, and inhibition of cancer cell migration.
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    
23. GENG Y, Wu W, Zhou L, Li J, et al
    Synergistic effects of LY294002 and ABT199 on the cell cycle in K562, HL60 and KG1a cells.
    Oncol Rep. 2021;45.
    PubMed     Abstract available
    
    
    March 2021
24. JING W, Zhou M, Chen R, Ye X, et al
    In vitro and ex vivo anti‑tumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2‑overexpressing leukemia cells.
    Oncol Rep. 2021;45:1142-1152.
    PubMed     Abstract available
    
    
    February 2021
25. ZHANG P, Wang Y, Qin M, Li D, et al
    Involvement of Blnk and Foxo1 in tumor suppression in BCRABL1transformed proB cells.
    Oncol Rep. 2021;45:693-705.
    PubMed     Abstract available
    
    
    January 2021
26. GONG Y, Deng J, Wu X
    Germline mutations and blood malignancy (Review).
    Oncol Rep. 2021;45:49-57.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.